Due to the PDOs’ predictable potential of the therapeutic responses in clinic (41), we developed a novel ESCC patient-specific organoid, which included CD276-positive ESCC PSO and the corresponding CD276-negative NC PSO, as primary testing models. This evidence concerns the gene CD276 and esophageal squamous cell carcinoma.